Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development

The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an overview of antibody development, PK characteristics, and the application of antibody PK/pharmacodynamics (PD) in research and development decision‐...

Full description

Saved in:
Bibliographic Details
Published inClinical and translational science Vol. 11; no. 6; pp. 540 - 552
Main Authors Ovacik, Meric, Lin, Kedan
Format Journal Article
LanguageEnglish
Published United States John Wiley and Sons Inc 01.11.2018
Subjects
Tutorial
Online AccessGet full text

Cover

Abstract The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an overview of antibody development, PK characteristics, and the application of antibody PK/pharmacodynamics (PD) in research and development decision‐making. We also discuss the general considerations for planning a nonclinical PK program and describe the types of PK studies that should be performed during early development of monoclonal antibodies.
AbstractList The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an overview of antibody development, PK characteristics, and the application of antibody PK/pharmacodynamics (PD) in research and development decision‐making. We also discuss the general considerations for planning a nonclinical PK program and describe the types of PK studies that should be performed during early development of monoclonal antibodies.
The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an overview of antibody development, PK characteristics, and the application of antibody PK/pharmacodynamics (PD) in research and development decision-making. We also discuss the general considerations for planning a nonclinical PK program and describe the types of PK studies that should be performed during early development of monoclonal antibodies.The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an overview of antibody development, PK characteristics, and the application of antibody PK/pharmacodynamics (PD) in research and development decision-making. We also discuss the general considerations for planning a nonclinical PK program and describe the types of PK studies that should be performed during early development of monoclonal antibodies.
Author Ovacik, Meric
Lin, Kedan
AuthorAffiliation 1 Department of Preclinical and Translational Pharmacokinetics Genentech, Inc. South San Francisco California USA
2 Clinical Pharmacology NGM Biopharmaceuticals, Inc. South San Francisco California USA
AuthorAffiliation_xml – name: 1 Department of Preclinical and Translational Pharmacokinetics Genentech, Inc. South San Francisco California USA
– name: 2 Clinical Pharmacology NGM Biopharmaceuticals, Inc. South San Francisco California USA
Author_xml – sequence: 1
  givenname: Meric
  surname: Ovacik
  fullname: Ovacik, Meric
  organization: Genentech, Inc
– sequence: 2
  givenname: Kedan
  surname: Lin
  fullname: Lin, Kedan
  email: kiln@ngmbio.com
  organization: NGM Biopharmaceuticals, Inc
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29877608$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1LJDEQhoMofh_8A0uO62E06e58zEWQ0d0VFAXHmxDS6RqNppMxySjz7zc6OriCm0NSRZ5636JqC6364AGhPUoOaDmHJqcDWjEuVtAmFawaSMKr1WXMmg20ldIDIbzmkq2jjWooheBEbqLb8SyHaLXDweOL4INxwZfs2Gfbhm6Or-517LUJj9ZDtiZh7Tt8lhMeBZ9sB1FnWyJsPT7V0c3xCTyDC9MefN5BaxPtEuy-v9vo5tfpePRncH75-2x0fD4wjaRiMKkJH8q2IcB4oyVwYWRHTGm-rsSw7oioO2G0ZJPWNEIwzjTvtIDXmzYt1NvoaKE7nbU9dKZYR-3UNNpex7kK2qp_f7y9V3fhWfGq4pTKIvDzXSCGpxmkrHqbDDinPYRZUhVhlHPGpSjoj89eS5OPkRZgfwGYGFKKMFkilKjXdamyLvW2rsIefmGNzW8DLW1a97-KF-tg_r20Go2vFxV_AWlSqFk
CitedBy_id crossref_primary_10_1016_j_vetimm_2023_110574
crossref_primary_10_1080_17474086_2022_2023007
crossref_primary_10_1186_s43088_023_00361_0
crossref_primary_10_1002_jcph_2322
crossref_primary_10_1136_jitc_2021_002663
crossref_primary_10_3390_cancers14225678
crossref_primary_10_1080_00498254_2024_2371921
crossref_primary_10_1016_j_str_2024_08_022
crossref_primary_10_1002_onco_13577
crossref_primary_10_1186_s40364_022_00373_5
crossref_primary_10_1021_acs_jcim_3c01500
crossref_primary_10_1016_j_bcp_2024_116303
crossref_primary_10_1016_j_xphs_2024_07_009
crossref_primary_10_1002_btpr_3371
crossref_primary_10_3389_fphar_2024_1427325
crossref_primary_10_1039_D2AN01032A
crossref_primary_10_3390_antib13030054
crossref_primary_10_1093_abt_tbae007
crossref_primary_10_1021_acs_molpharmaceut_0c00127
crossref_primary_10_2139_ssrn_4113877
crossref_primary_10_3389_fphar_2022_958543
crossref_primary_10_3389_fphar_2022_1040951
crossref_primary_10_1038_s41375_023_02010_y
crossref_primary_10_1016_j_prp_2025_155864
crossref_primary_10_1016_j_clinpr_2021_100130
crossref_primary_10_1038_s41598_025_87316_w
crossref_primary_10_1021_acs_jmedchem_4c00802
crossref_primary_10_1177_1091581821998945
crossref_primary_10_1016_j_tim_2022_12_003
crossref_primary_10_1007_s00280_023_04541_8
crossref_primary_10_3390_pharmaceutics15051552
crossref_primary_10_1002_cpt_2929
crossref_primary_10_1007_s40259_018_0289_y
crossref_primary_10_3390_ijms24010746
crossref_primary_10_1016_j_ijpharm_2024_124877
crossref_primary_10_1007_s11307_024_01901_5
crossref_primary_10_3390_vaccines9020145
crossref_primary_10_1080_17425247_2023_2184343
crossref_primary_10_1111_bcp_15937
crossref_primary_10_3390_ijms21207496
crossref_primary_10_1080_17425247_2022_2081682
crossref_primary_10_3390_cancers15010246
crossref_primary_10_1002_cpt_3303
crossref_primary_10_1002_jcph_2227
crossref_primary_10_1007_s40121_021_00572_x
crossref_primary_10_1093_jpids_piad113
crossref_primary_10_1177_1535370221990870
crossref_primary_10_1007_s00280_024_04643_x
crossref_primary_10_1016_j_yrtph_2021_104890
crossref_primary_10_1080_21645515_2023_2274222
crossref_primary_10_3390_pharmaceutics13122105
crossref_primary_10_1080_00498254_2024_2383925
crossref_primary_10_4155_bio_2023_0115
crossref_primary_10_1007_s11523_021_00832_3
crossref_primary_10_1021_acs_analchem_3c03158
crossref_primary_10_1146_annurev_pharmtox_022820_093805
crossref_primary_10_1016_j_ijpharm_2020_120164
crossref_primary_10_1016_j_isci_2021_103014
crossref_primary_10_1080_19420862_2021_1895540
crossref_primary_10_1002_advs_202202907
crossref_primary_10_3389_fimmu_2024_1395655
crossref_primary_10_3390_pharmaceutics14071441
crossref_primary_10_3892_mco_2023_2643
crossref_primary_10_3389_fphar_2022_864768
crossref_primary_10_1016_j_omton_2024_200821
crossref_primary_10_1111_bcp_16057
crossref_primary_10_1016_j_ejps_2024_106744
crossref_primary_10_1016_j_smim_2021_101514
crossref_primary_10_1080_21645515_2021_1908060
crossref_primary_10_1186_s12967_024_05728_0
crossref_primary_10_1016_j_tmrv_2023_150767
crossref_primary_10_1016_j_xphs_2023_01_001
crossref_primary_10_32607_actanaturae_11611
crossref_primary_10_1002_cmdc_202100135
crossref_primary_10_1002_psp4_13204
crossref_primary_10_1177_1078155220979048
crossref_primary_10_22159_ajpcr_2024v17i8_51398
crossref_primary_10_1021_acsbiomaterials_2c00808
crossref_primary_10_1073_pnas_2306700120
crossref_primary_10_1016_j_biomaterials_2020_120635
crossref_primary_10_1016_j_ejps_2023_106450
crossref_primary_10_1016_j_xphs_2022_04_005
crossref_primary_10_15252_emmm_201809824
crossref_primary_10_1007_s12257_024_00147_w
crossref_primary_10_1080_17425255_2023_2272598
crossref_primary_10_1088_2043_6262_ac2747
crossref_primary_10_1111_bcp_15233
crossref_primary_10_1080_19420862_2021_2008790
crossref_primary_10_1038_s41557_021_00866_0
crossref_primary_10_1021_acs_molpharmaceut_2c00102
crossref_primary_10_1016_j_mcpro_2023_100690
crossref_primary_10_1136_jitc_2023_006948
crossref_primary_10_3892_ijo_2022_5302
crossref_primary_10_1002_jcph_2360
crossref_primary_10_1073_pnas_2214278119
crossref_primary_10_4155_bio_2023_0179
crossref_primary_10_1007_s11095_025_03825_3
crossref_primary_10_3389_fmicb_2022_960937
crossref_primary_10_1080_17512433_2023_2257136
crossref_primary_10_1002_adhm_202304003
crossref_primary_10_3389_fonc_2021_691685
crossref_primary_10_1007_s40259_024_00682_1
crossref_primary_10_1080_14712598_2022_2033204
crossref_primary_10_3390_pharmaceutics12121147
crossref_primary_10_1016_j_bone_2022_116456
crossref_primary_10_1038_s41598_021_86551_1
crossref_primary_10_1080_08941939_2021_1874081
crossref_primary_10_1111_cts_13192
crossref_primary_10_3389_fimmu_2022_863831
crossref_primary_10_1016_j_imbio_2020_151982
crossref_primary_10_1208_s12248_021_00557_1
crossref_primary_10_3389_fneur_2022_870799
crossref_primary_10_1002_prp2_535
crossref_primary_10_1177_2475530320950271
crossref_primary_10_1080_1061186X_2023_2295803
crossref_primary_10_1021_acsptsci_0c00134
crossref_primary_10_1080_19420862_2023_2167189
crossref_primary_10_3390_pharmaceutics15051477
crossref_primary_10_1007_s00280_021_04319_w
crossref_primary_10_1016_j_taap_2024_117034
crossref_primary_10_3389_fimmu_2021_721328
crossref_primary_10_1038_s41591_024_03101_8
crossref_primary_10_1016_j_ijpharm_2023_123687
crossref_primary_10_1016_j_xphs_2024_06_013
crossref_primary_10_3390_v16081345
crossref_primary_10_1111_jth_15244
crossref_primary_10_1016_j_clinthera_2023_10_016
crossref_primary_10_3390_cancers13040779
crossref_primary_10_1021_acs_analchem_0c04903
crossref_primary_10_1002_jcph_1706
crossref_primary_10_1093_ndt_gfac056
crossref_primary_10_1111_vox_13710
crossref_primary_10_1016_j_isci_2024_110115
crossref_primary_10_1124_pharmrev_121_000317
crossref_primary_10_1021_acs_bioconjchem_0c00551
crossref_primary_10_1038_s41586_021_03258_z
crossref_primary_10_1007_s10517_024_06265_y
crossref_primary_10_1016_j_tips_2022_12_005
crossref_primary_10_1002_advs_202205389
crossref_primary_10_1038_s41598_020_73255_1
crossref_primary_10_1111_apt_16937
crossref_primary_10_30895_2221_996X_2023_23_2_173_180
crossref_primary_10_1136_jitc_2023_007659
crossref_primary_10_1186_s43141_022_00421_5
crossref_primary_10_1038_s41540_025_00495_0
crossref_primary_10_1016_j_heares_2024_108950
crossref_primary_10_1111_bcp_15608
crossref_primary_10_1016_j_bcp_2021_114468
crossref_primary_10_1158_1078_0432_CCR_23_1683
crossref_primary_10_1056_NEJMoa2405008
crossref_primary_10_1002_cpt_3353
crossref_primary_10_1002_jlcr_4049
crossref_primary_10_3390_pharmaceutics17030377
crossref_primary_10_1002_cpt_3513
crossref_primary_10_1016_j_talanta_2022_123842
crossref_primary_10_3389_fchem_2022_863118
crossref_primary_10_1007_s40620_023_01845_z
crossref_primary_10_1016_j_peptides_2021_170714
crossref_primary_10_1002_cpt_2308
crossref_primary_10_1186_s41181_020_00109_6
crossref_primary_10_1002_psp4_12711
crossref_primary_10_1097_FTD_0000000000000681
crossref_primary_10_1007_s10928_023_09899_z
crossref_primary_10_1007_s43450_022_00265_7
crossref_primary_10_1016_j_intimp_2024_112371
crossref_primary_10_3389_fphar_2022_855743
crossref_primary_10_1016_j_jconrel_2021_07_029
crossref_primary_10_3390_pharmaceutics14091766
crossref_primary_10_1016_j_drudis_2022_06_011
crossref_primary_10_3389_fimmu_2023_1266450
crossref_primary_10_3389_fmed_2022_1071086
crossref_primary_10_3389_fmed_2021_741855
crossref_primary_10_1016_j_jpba_2020_113415
crossref_primary_10_1177_10781552241228827
crossref_primary_10_1007_s10637_021_01084_8
crossref_primary_10_1016_j_comtox_2023_100278
crossref_primary_10_3390_ph14030247
crossref_primary_10_7554_eLife_63784
crossref_primary_10_1021_acsnano_3c13039
crossref_primary_10_3389_fphar_2024_1434961
crossref_primary_10_3390_pharmaceutics15082129
crossref_primary_10_1007_s40261_020_00978_4
crossref_primary_10_1097_COH_0000000000000742
Cites_doi 10.1093/toxsci/kfw037
10.1016/j.amsu.2014.09.001
10.4161/mabs.4.2.19387
10.1002/cpt.628
10.1038/nrd2242
10.1038/nrd4309
10.1073/pnas.1616408114
10.4161/mabs.1.6.10015
10.1016/j.coph.2008.08.002
10.1002/jcph.840
10.1038/clpt.2008.170
10.2147/DDDT.S121520
10.1038/ni.2392
10.4161/mabs.4.2.19364
10.4161/mabs.2.2.11221
10.1093/glycob/cwl057
10.4161/mabs.22189
10.4161/mabs.3.5.16983
10.1002/psp4.12014
10.1016/j.addr.2015.02.005
10.1038/nrc3930
10.1080/19420862.2017.1323160
10.1208/s12248-012-9408-8
10.1093/protein/gzq009
10.3324/haematol.2008.001628
10.1208/s12248-013-9495-1
10.1016/j.tips.2016.09.005
10.1021/bc100261d
10.1126/science.1158545
10.3389/fphar.2017.00460
10.1126/scitranslmed.3009835
10.1201/EBK1439802687
10.1002/bdd.1952
10.1083/jcb.98.4.1170
10.2133/dmpk.DMPK-11-SH-059
10.1080/17425255.2017.1360280
10.1016/j.ejpb.2016.01.009
10.1056/NEJMoa063842
10.1038/256495a0
10.1208/s12248-012-9369-y
10.1055/s-0034-1368173
10.2165/11530960-000000000-00000
10.1038/nri2761
10.1111/j.1365-2125.2007.02914.x
10.4161/mabs.26436
10.1074/jbc.M115.692434
10.4161/mabs.24981
10.1002/jps.21183
10.3390/biomedicines4020012
10.3389/fphar.2014.00174
10.1073/pnas.1408766112
10.2165/11537430-000000000-00000
10.1089/cbr.2009.0627
10.4161/mabs.3.1.13799
10.1111/cts.12459
10.1080/19420862.2016.1167294
10.1016/j.drudis.2006.08.005
10.1002/jps.22276
10.2165/11535960-000000000-00000
10.1002/jcph.365
10.1002/psp4.12162
10.1158/0008-5472.CAN-10-2277
10.1002/bdd.1994
10.1007/s40262-015-0361-4
10.1007/s00280-011-1806-6
10.1208/s12248-012-9367-0
10.1002/jps.20178
10.1073/pnas.91.12.5705
10.1093/glycob/cwr027
10.3389/fimmu.2015.00109
10.1128/AAC.01285-13
10.1038/nri2155
10.4161/mabs.23684
10.1111/bph.14021
10.1007/s10928-010-9156-2
10.1080/19420862.2016.1269580
10.1016/j.ijpharm.2013.02.030
10.1177/0091270009337134
10.2741/2749
10.1002/jps.24430
10.1016/j.molimm.2015.01.003
10.1080/19420862.2015.1136043
10.4161/mabs.26008
10.1200/JCO.2014.58.1082
10.1080/19420862.2016.1267089
10.4161/mabs.28719
10.1016/j.jim.2005.06.014
10.1073/pnas.1421779112
10.1002/psp4.12130
10.1517/17425255.2012.643868
10.1158/1535-7163.MCT-17-0657
ContentType Journal Article
Copyright 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics
2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Copyright_xml – notice: 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics
– notice: 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
DBID 24P
AAYXX
CITATION
NPM
7X8
5PM
DOI 10.1111/cts.12567
DatabaseName Wiley Online Library Open Access
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
CrossRef

PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Ovacik and Lin
EISSN 1752-8062
EndPage 552
ExternalDocumentID PMC6226118
29877608
10_1111_cts_12567
CTS12567
Genre article
Journal Article
GroupedDBID ---
05W
0R~
10A
1OC
24P
29B
31~
4.4
52S
53G
5GY
5VS
7X7
8-1
8FE
8FH
8FI
8FJ
AAHHS
AANHP
AAZKR
ABDBF
ABUWG
ACBWZ
ACCFJ
ACCMX
ACRPL
ACUHS
ACXQS
ACYXJ
ADKYN
ADNMO
ADZMN
ADZOD
AEEZP
AEQDE
AFBPY
AFKRA
AFZJQ
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AVUZU
BBNVY
BDRZF
BENPR
BHPHI
BPHCQ
BRXPI
BVXVI
CAG
CCPQU
COF
CS3
DIK
EBD
EBS
EJD
EMOBN
ESX
F5P
FEDTE
FYUFA
G-S
GODZA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IAO
IHR
ITC
KQ8
LH4
LK8
LW6
M7P
MY~
O9-
OIG
OK1
P2P
PIMPY
PQQKQ
PROAC
QB0
ROL
RPM
SUPJJ
SV3
TUS
UKHRP
WIN
XG1
AAYXX
AGQPQ
CITATION
PHGZM
PHGZT
NPM
7X8
PQGLB
5PM
ID FETCH-LOGICAL-c4817-f30698b40e564a8e67c8d0c75232793d073d7ca85fbc477565a6da7ea6da14be3
IEDL.DBID 24P
ISSN 1752-8054
1752-8062
IngestDate Thu Aug 21 14:01:07 EDT 2025
Thu Jul 10 23:14:21 EDT 2025
Thu Apr 03 07:05:20 EDT 2025
Tue Jul 01 01:05:33 EDT 2025
Thu Apr 24 23:06:03 EDT 2025
Wed Jan 22 16:21:47 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License Attribution-NonCommercial
2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4817-f30698b40e564a8e67c8d0c75232793d073d7ca85fbc477565a6da7ea6da14be3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.12567
PMID 29877608
PQID 2051665687
PQPubID 23479
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6226118
proquest_miscellaneous_2051665687
pubmed_primary_29877608
crossref_primary_10_1111_cts_12567
crossref_citationtrail_10_1111_cts_12567
wiley_primary_10_1111_cts_12567_CTS12567
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2018
PublicationDateYYYYMMDD 2018-11-01
PublicationDate_xml – month: 11
  year: 2018
  text: November 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Clinical and translational science
PublicationTitleAlternate Clin Transl Sci
PublicationYear 2018
Publisher John Wiley and Sons Inc
Publisher_xml – name: John Wiley and Sons Inc
References 2017; 6
2010; 10
2017; 8
2015; 104
2015; 33
2013; 447
2016; 101
2008; 8
2012; 14
2012; 13
2013; 5
2016; 37
2017; 114
2017; 9
2009; 49
2010; 23
2010; 21
2014; 5
2013; 15
2015; 290
2014; 3
2010; 24
2001
2013; 57
2011; 71
1984; 98
2005; 304
2007; 6
2007; 7
2011; 21
2014; 13
2012; 27
2015; 91
2007; 64
2012; 69
2010; 2
2014; 6
2016; 151
2007; 17
2015; 15
2009; 24
2015; 6
2010; 37
2015; 4
2010
2006; 11
2015; 55
2016; 10
2007
2008; 13
2008; 97
2008; 321
2014; 111
2011; 3
1975; 256
2016; 55
2006; 355
2016; 4
2015; 67
2018; 17
2010; 49
2004; 93
2015; 112
2017; 10
2017; 57
2011; 50
2017
2016
2014; 74
2008; 84
2017; 101
1994; 91
2012; 4
2009; 1
2016; 8
2010; 95
2011; 100
2012; 8
e_1_2_12_6_1
e_1_2_12_2_1
e_1_2_12_17_1
e_1_2_12_20_1
e_1_2_12_66_1
e_1_2_12_43_1
e_1_2_12_85_1
e_1_2_12_24_1
e_1_2_12_47_1
e_1_2_12_89_1
e_1_2_12_62_1
e_1_2_12_81_1
e_1_2_12_100_1
e_1_2_12_28_1
e_1_2_12_31_1
e_1_2_12_77_1
e_1_2_12_54_1
e_1_2_12_96_1
e_1_2_12_35_1
e_1_2_12_58_1
e_1_2_12_12_1
e_1_2_12_73_1
e_1_2_12_50_1
e_1_2_12_92_1
e_1_2_12_3_1
e_1_2_12_18_1
e_1_2_12_21_1
e_1_2_12_44_1
e_1_2_12_63_1
e_1_2_12_86_1
e_1_2_12_25_1
e_1_2_12_48_1
e_1_2_12_67_1
e_1_2_12_40_1
e_1_2_12_82_1
Vicini P. (e_1_2_12_83_1) 2016
e_1_2_12_29_1
e_1_2_12_32_1
e_1_2_12_55_1
e_1_2_12_74_1
e_1_2_12_97_1
e_1_2_12_36_1
e_1_2_12_59_1
e_1_2_12_78_1
e_1_2_12_13_1
e_1_2_12_51_1
e_1_2_12_70_1
e_1_2_12_93_1
e_1_2_12_19_1
e_1_2_12_38_1
e_1_2_12_41_1
e_1_2_12_87_1
e_1_2_12_22_1
e_1_2_12_64_1
e_1_2_12_45_1
e_1_2_12_26_1
e_1_2_12_68_1
Almagro J.C. (e_1_2_12_7_1) 2008; 13
e_1_2_12_60_1
e_1_2_12_49_1
e_1_2_12_52_1
e_1_2_12_98_1
e_1_2_12_33_1
e_1_2_12_75_1
e_1_2_12_56_1
e_1_2_12_37_1
e_1_2_12_79_1
e_1_2_12_14_1
e_1_2_12_90_1
e_1_2_12_8_1
e_1_2_12_10_1
e_1_2_12_94_1
e_1_2_12_71_1
e_1_2_12_5_1
e_1_2_12_1_1
e_1_2_12_16_1
e_1_2_12_39_1
e_1_2_12_42_1
e_1_2_12_65_1
e_1_2_12_88_1
e_1_2_12_23_1
e_1_2_12_46_1
e_1_2_12_69_1
Cruse J.M. (e_1_2_12_4_1) 2010
e_1_2_12_80_1
e_1_2_12_61_1
e_1_2_12_84_1
e_1_2_12_27_1
e_1_2_12_30_1
e_1_2_12_53_1
e_1_2_12_76_1
e_1_2_12_99_1
e_1_2_12_34_1
e_1_2_12_57_1
e_1_2_12_15_1
e_1_2_12_91_1
e_1_2_12_11_1
e_1_2_12_72_1
e_1_2_12_95_1
e_1_2_12_9_1
References_xml – volume: 6
  start-page: 120
  year: 2007
  end-page: 126
  article-title: Preclinical safety testing of monoclonal antibodies: the significance of species relevance
  publication-title: Nat. Rev. Drug Discov.
– volume: 37
  start-page: 221
  year: 2010
  end-page: 242
  article-title: Modeling the efficacy of trastuzumab‐DM1, an antibody drug conjugate, in mice
  publication-title: J. Pharmacokinet. Pharmacodyn.
– volume: 55
  start-page: 789
  year: 2016
  end-page: 805
  article-title: Potential Sources of Inter‐Subject Variability in Monoclonal Antibody Pharmacokinetics
  publication-title: Clin. Pharmacokinet.
– volume: 6
  start-page: 109
  year: 2015
  article-title: Immunogenicity of Anti‐TNF‐alpha Biotherapies: II. Clinical Relevance of Methods Used for Anti‐Drug Antibody Detection
  publication-title: Front Immunol.
– volume: 13
  start-page: 1619
  year: 2008
  end-page: 1633
  article-title: Humanization of antibodies
  publication-title: Front. Biosci.
– volume: 6
  start-page: 8
  year: 2017
  end-page: 10
  article-title: Commentary on Pharmacometrics for Immunotherapy
  publication-title: CPT Pharmacometrics Syst. Pharmacol.
– volume: 14
  start-page: 559
  year: 2012
  end-page: 570
  article-title: Mechanistic determinants of biotherapeutics absorption following SC administration
  publication-title: AAPS J.
– volume: 355
  start-page: 1018
  year: 2006
  end-page: 1028
  article-title: Cytokine storm in a phase 1 trial of the anti‐CD28 monoclonal antibody TGN1412
  publication-title: N. Engl. J. Med.
– year: 2001
– volume: 97
  start-page: 2497
  year: 2008
  end-page: 2523
  article-title: Past, present, and future technologies for oral delivery of therapeutic proteins
  publication-title: J. Pharm. Sci.
– volume: 6
  start-page: 11
  year: 2017
  end-page: 20
  article-title: Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti‐PD‐1 Antibody Pembrolizumab
  publication-title: CPT Pharmacometrics Syst. Pharmacol.
– volume: 10
  start-page: 301
  year: 2010
  end-page: 316
  article-title: Therapeutic antibodies for autoimmunity and inflammation
  publication-title: Nat. Rev. Immunol.
– volume: 91
  start-page: 109
  year: 2015
  end-page: 124
  article-title: The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
  publication-title: Adv. Drug. Deliv. Rev.
– volume: 4
  start-page: 243
  year: 2012
  end-page: 255
  article-title: Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration
  publication-title: MAbs
– year: 2017
  article-title: Widespread brain distribution and activity following i.c.v. infusion of anti‐beta‐secretase (BACE1) in nonhuman primates
  publication-title: Br. J. Pharmacol.
– volume: 11
  start-page: 905
  year: 2006
  end-page: 910
  article-title: Is the oral route possible for peptide and protein drug delivery?
  publication-title: Drug Discov. Today
– volume: 5
  start-page: 896
  year: 2013
  end-page: 903
  article-title: Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys
  publication-title: MAbs
– volume: 9
  start-page: 167
  year: 2017
  end-page: 181
  article-title: Antibodies to watch in 2017
  publication-title: MAbs.
– volume: 8
  start-page: 141
  year: 2012
  end-page: 160
  article-title: Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
  publication-title: Expert Opin. Drug Metab. Toxicol.
– volume: 37
  start-page: 75
  year: 2016
  end-page: 92
  article-title: Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini‐review on fundamental concepts and applications
  publication-title: Biopharm. Drug Dispos.
– volume: 95
  start-page: 135
  year: 2010
  end-page: 143
  article-title: Anti‐CD20 monoclonal antibodies: historical and future perspectives
  publication-title: Haematologica
– volume: 6
  start-page: 261ra154
  year: 2014
  article-title: Therapeutic bispecific antibodies cross the blood‐brain barrier in nonhuman primates
  publication-title: Sci. Transl. Med.
– volume: 3
  start-page: 422
  year: 2011
  end-page: 430
  article-title: Neonatal Fc receptor and IgG‐based therapeutics
  publication-title: MAbs
– volume: 49
  start-page: 1382
  year: 2009
  end-page: 1402
  article-title: Interspecies scaling of therapeutic monoclonal antibodies: initial look
  publication-title: J. Clin. Pharmacol.
– volume: 4
  start-page: 267
  year: 2012
  end-page: 273
  article-title: Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys
  publication-title: MAbs
– volume: 93
  start-page: 2645
  year: 2004
  end-page: 2668
  article-title: Antibody pharmacokinetics and pharmacodynamics
  publication-title: J. Pharm. Sci.
– volume: 5
  start-page: 576
  year: 2013
  end-page: 586
  article-title: Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
  publication-title: MAbs
– volume: 57
  start-page: 616
  year: 2017
  end-page: 626
  article-title: Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
  publication-title: J. Clin. Pharmacol.
– volume: 304
  start-page: 189
  year: 2005
  end-page: 195
  article-title: An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen
  publication-title: J. Immunol. Methods
– volume: 50
  start-page: 131
  year: 2011
  end-page: 142
  article-title: Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first‐in‐human prediction
  publication-title: Clin. Pharmacokinet.
– volume: 10
  start-page: 4005
  year: 2016
  end-page: 4016
  article-title: Determination of the starting dose in the first‐in‐human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013
  publication-title: Drug Des Devel Ther
– volume: 112
  start-page: 5997
  year: 2015
  end-page: 6002
  article-title: Charge‐mediated influence of the antibody variable domain on FcRn‐dependent pharmacokinetics
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 5
  start-page: 826
  year: 2013
  end-page: 837
  article-title: Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
  publication-title: MAbs
– volume: 57
  start-page: 6147
  year: 2013
  end-page: 6153
  article-title: A novel investigational Fc‐modified humanized monoclonal antibody, motavizumab‐YTE, has an extended half‐life in healthy adults
  publication-title: Antimicrob. Agents Chemother.
– year: 2016
  article-title: Clinical Pharmacology: a Discipline at the Nexus Between Translational Science and Precision Medicine: Commentary on “Enhancing Value of Clinical Pharmacodynamics in Oncology Drug Development: An Alliance Between Quantitative Pharmacology and Translational Science”
  publication-title: Clin. Pharmacol. Ther.
– volume: 67
  start-page: 95
  issue: 2 Pt A
  year: 2015
  end-page: 106
  article-title: Alternative molecular formats and therapeutic applications for bispecific antibodies
  publication-title: Mol. Immunol.
– volume: 9
  start-page: 756
  year: 2017
  end-page: 766
  article-title: Pharmacokinetic de‐risking tools for selection of monoclonal antibody lead candidates
  publication-title: MAbs
– volume: 4
  year: 2016
  article-title: Plant Toxin‐Based Immunotoxins for Cancer Therapy: A Short Overview
  publication-title: Biomedicines.
– volume: 24
  start-page: 155
  year: 2009
  end-page: 161
  article-title: Affinity and avidity in antibody‐based tumor targeting
  publication-title: Cancer Biother. Radiopharm.
– volume: 64
  start-page: 278
  year: 2007
  end-page: 291
  article-title: Population pharmacokinetics‐pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response
  publication-title: Br. J. Clin. Pharmacol.
– volume: 13
  start-page: 419
  year: 2014
  end-page: 431
  article-title: Lessons learned from the fate of AstraZeneca's drug pipeline: a five‐dimensional framework
  publication-title: Nat. Rev. Drug Discov.
– volume: 84
  start-page: 548
  year: 2008
  end-page: 558
  article-title: Monoclonal antibody pharmacokinetics and pharmacodynamics
  publication-title: Clin. Pharmacol. Ther.
– volume: 9
  start-page: 213
  year: 2017
  end-page: 230
  article-title: Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells
  publication-title: MAbs
– volume: 13
  start-page: 1129
  year: 2012
  end-page: 1132
  article-title: Immunology beats cancer: a blueprint for successful translation
  publication-title: Nat. Immunol.
– volume: 55
  start-page: S29
  issue: Suppl 3
  year: 2015
  end-page: S38
  article-title: Assessments of antibody biodistribution
  publication-title: J. Clin. Pharmacol.
– volume: 151
  start-page: 245
  year: 2016
  end-page: 260
  article-title: Therapeutic Antibody‐Induced Vascular Toxicity Due to Off‐Target Activation of Nitric Oxide in Cynomolgus Monkeys
  publication-title: Toxicol. Sci.
– volume: 37
  start-page: 1009
  year: 2016
  end-page: 1028
  article-title: Coming‐of‐Age of Antibodies in Cancer Therapeutics
  publication-title: Trends Pharmacol. Sci.
– volume: 8
  start-page: 460
  year: 2017
  article-title: Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti‐TNF Biologics
  publication-title: Front. Pharmacol.
– volume: 100
  start-page: 354
  year: 2011
  end-page: 387
  article-title: Impact of product‐related factors on immunogenicity of biotherapeutics
  publication-title: J. Pharm. Sci.
– volume: 98
  start-page: 1170
  year: 1984
  end-page: 1177
  article-title: Internalization and degradation of macrophage Fc receptors bound to polyvalent immune complexes
  publication-title: J. Cell Biol.
– volume: 21
  start-page: 949
  year: 2011
  end-page: 959
  article-title: High‐mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans
  publication-title: Glycobiology
– volume: 4
  start-page: 495
  year: 2015
  end-page: 497
  article-title: Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
  publication-title: CPT Pharmacometrics Syst Pharmacol
– volume: 24
  start-page: 89
  year: 2010
  end-page: 98
  article-title: Bispecific antibodies for cancer immunotherapy: Current perspectives
  publication-title: BioDrugs
– volume: 290
  start-page: 29732
  year: 2015
  end-page: 29741
  article-title: Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics
  publication-title: J. Biol. Chem.
– volume: 101
  start-page: 582
  year: 2017
  end-page: 584
  article-title: Toward greater insights on pharmacokinetics and exposure‐response relationships for therapeutic biologics in oncology drug development
  publication-title: Clin. Pharmacol. Ther.
– volume: 10
  start-page: 147
  year: 2017
  end-page: 162
  article-title: Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
  publication-title: Clin. Transl. Sci.
– volume: 37
  start-page: 51
  year: 2016
  end-page: 65
  article-title: Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development
  publication-title: Biopharm. Drug Dispos.
– volume: 8
  start-page: 991
  year: 2016
  end-page: 997
  article-title: Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A
  publication-title: MAbs
– volume: 21
  start-page: 2153
  year: 2010
  end-page: 2163
  article-title: Effects of charge on antibody tissue distribution and pharmacokinetics
  publication-title: Bioconjug. Chem.
– volume: 14
  start-page: 554
  year: 2012
  end-page: 558
  article-title: Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics
  publication-title: AAPS J.
– volume: 49
  start-page: 633
  year: 2010
  end-page: 659
  article-title: Population pharmacokinetics of therapeutic monoclonal antibodies
  publication-title: Clin. Pharmacokinet.
– year: 2007
– volume: 13
  start-page: 1117
  year: 2008
  end-page: 1129
  article-title: Human antibody libraries: a race to engineer and explore a larger diversity
  publication-title: Front. Biosci.
– volume: 3
  start-page: 61
  year: 2011
  end-page: 66
  article-title: Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
  publication-title: MAbs
– volume: 23
  start-page: 385
  year: 2010
  end-page: 392
  article-title: Reduced elimination of IgG antibodies by engineering the variable region
  publication-title: Protein Eng. Des. Sel.
– volume: 15
  start-page: 933
  year: 2013
  end-page: 940
  article-title: Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop
  publication-title: AAPS J.
– volume: 15
  start-page: 361
  year: 2015
  end-page: 370
  article-title: Building better monoclonal antibody‐based therapeutics
  publication-title: Nat. Rev. Cancer.
– volume: 256
  start-page: 495
  year: 1975
  end-page: 497
  article-title: Continuous cultures of fused cells secreting antibody of predefined specificity
  publication-title: Nature
– volume: 5
  start-page: 297
  year: 2013
  end-page: 305
  article-title: Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human
  publication-title: MAbs
– volume: 17
  start-page: 104
  year: 2007
  end-page: 118
  article-title: Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N‐linked Fc oligosaccharides: the high‐mannose, hybrid, and complex types
  publication-title: Glycobiology
– year: 2010
– volume: 15
  start-page: 30
  year: 2013
  end-page: 40
  article-title: Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics
  publication-title: AAPS J.
– volume: 8
  start-page: 620
  year: 2008
  end-page: 626
  article-title: Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
  publication-title: Curr. Opin. Pharmacol.
– volume: 114
  start-page: 944
  year: 2017
  end-page: 949
  article-title: Biophysical properties of the clinical‐stage antibody landscape
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 71
  start-page: 2250
  year: 2011
  end-page: 2259
  article-title: Influence of affinity and antigen internalization on the uptake and penetration of Anti‐HER2 antibodies in solid tumors
  publication-title: Cancer Res.
– volume: 91
  start-page: 5705
  year: 1994
  end-page: 5709
  article-title: Macromolecular permeability across the blood‐nerve and blood‐brain barriers
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 74
  start-page: 343
  year: 2014
  end-page: 349
  article-title: Subcutaneous Administration of Monoclonal Antibodies in Oncology
  publication-title: Geburtshilfe Frauenheilkd.
– volume: 27
  start-page: 354
  year: 2012
  end-page: 359
  article-title: Prediction of human plasma concentration‐time profiles of monoclonal antibodies from monkey data by a species‐invariant time method
  publication-title: Drug Metab. Pharmacokinet.
– volume: 1
  start-page: 539
  year: 2009
  end-page: 547
  article-title: Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
  publication-title: MAbs
– year: 2017
  article-title: Biological anti‐TNF drugs: Immunogenicity underlying treatment failure and adverse events
  publication-title: Expert Opin. Drug Metab. Toxicol.
– volume: 4
  start-page: 753
  year: 2012
  end-page: 760
  article-title: A strategy for risk mitigation of antibodies with fast clearance
  publication-title: MAbs
– volume: 447
  start-page: 75
  year: 2013
  end-page: 93
  article-title: Approaches for enhancing oral bioavailability of peptides and proteins
  publication-title: Int. J. Pharm.
– volume: 6
  start-page: 1103
  year: 2014
  end-page: 1113
  article-title: Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum
  publication-title: MAbs
– volume: 7
  start-page: 715
  year: 2007
  end-page: 725
  article-title: FcRn: the neonatal Fc receptor comes of age
  publication-title: Nat. Rev. Immunol.
– volume: 17
  start-page: 776
  year: 2018
  end-page: 785
  article-title: Relative Target Affinities of T‐Cell‐Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
  publication-title: Mol. Cancer Ther.
– volume: 101
  start-page: 53
  year: 2016
  end-page: 61
  article-title: Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain
  publication-title: Eur. J. Pharm. Biopharm.
– volume: 104
  start-page: 1885
  year: 2015
  end-page: 1898
  article-title: Developability assessment during the selection of novel therapeutic antibodies
  publication-title: J. Pharm. Sci.
– volume: 321
  start-page: 974
  year: 2008
  end-page: 977
  article-title: Tumor regression in cancer patients by very low doses of a T cell‐engaging antibody
  publication-title: Science
– volume: 8
  start-page: 593
  year: 2016
  end-page: 603
  article-title: Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti‐PD‐L1 monoclonal antibody, an immune checkpoint inhibitor
  publication-title: MAbs
– volume: 3
  start-page: 113
  year: 2014
  end-page: 116
  article-title: The history of monoclonal antibody development—Progress, remaining challenges and future innovations
  publication-title: Ann. Med. Surg. (Lond).
– volume: 2
  start-page: 129
  year: 2010
  end-page: 136
  article-title: Catumaxomab: clinical development and future directions
  publication-title: MAbs
– volume: 33
  start-page: 2158
  year: 2015
  end-page: 2165
  article-title: Clinical Development Strategies and Outcomes in First‐in‐Human Trials of Monoclonal Antibodies
  publication-title: J. Clin. Oncol.
– year: 2017
– volume: 69
  start-page: 1063
  year: 2012
  end-page: 1069
  article-title: Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual‐action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
  publication-title: Cancer Chemother. Pharmacol.
– volume: 5
  start-page: 174
  year: 2014
  article-title: Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research
  publication-title: Front. Pharmacol
– volume: 111
  start-page: 18601
  year: 2014
  end-page: 18606
  article-title: In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability
  publication-title: Proc. Natl. Acad. Sci. USA
– ident: e_1_2_12_55_1
  doi: 10.1093/toxsci/kfw037
– ident: e_1_2_12_6_1
  doi: 10.1016/j.amsu.2014.09.001
– ident: e_1_2_12_22_1
  doi: 10.4161/mabs.4.2.19387
– ident: e_1_2_12_53_1
  doi: 10.1002/cpt.628
– ident: e_1_2_12_70_1
  doi: 10.1038/nrd2242
– ident: e_1_2_12_50_1
  doi: 10.1038/nrd4309
– ident: e_1_2_12_58_1
  doi: 10.1073/pnas.1616408114
– ident: e_1_2_12_85_1
  doi: 10.4161/mabs.1.6.10015
– ident: e_1_2_12_49_1
  doi: 10.1016/j.coph.2008.08.002
– ident: e_1_2_12_37_1
  doi: 10.1002/jcph.840
– ident: e_1_2_12_48_1
– ident: e_1_2_12_33_1
  doi: 10.1038/clpt.2008.170
– ident: e_1_2_12_72_1
  doi: 10.2147/DDDT.S121520
– ident: e_1_2_12_12_1
  doi: 10.1038/ni.2392
– ident: e_1_2_12_21_1
  doi: 10.4161/mabs.4.2.19364
– ident: e_1_2_12_88_1
  doi: 10.4161/mabs.2.2.11221
– ident: e_1_2_12_44_1
  doi: 10.1093/glycob/cwl057
– ident: e_1_2_12_57_1
  doi: 10.4161/mabs.22189
– ident: e_1_2_12_98_1
  doi: 10.4161/mabs.3.5.16983
– ident: e_1_2_12_80_1
  doi: 10.1002/psp4.12014
– ident: e_1_2_12_99_1
  doi: 10.1016/j.addr.2015.02.005
– ident: e_1_2_12_2_1
  doi: 10.1038/nrc3930
– ident: e_1_2_12_59_1
  doi: 10.1080/19420862.2017.1323160
– ident: e_1_2_12_62_1
  doi: 10.1208/s12248-012-9408-8
– ident: e_1_2_12_10_1
– ident: e_1_2_12_69_1
– ident: e_1_2_12_41_1
  doi: 10.1093/protein/gzq009
– ident: e_1_2_12_14_1
  doi: 10.3324/haematol.2008.001628
– ident: e_1_2_12_100_1
  doi: 10.1208/s12248-013-9495-1
– ident: e_1_2_12_9_1
  doi: 10.1016/j.tips.2016.09.005
– ident: e_1_2_12_25_1
  doi: 10.1021/bc100261d
– ident: e_1_2_12_89_1
  doi: 10.1126/science.1158545
– ident: e_1_2_12_11_1
  doi: 10.3389/fphar.2017.00460
– ident: e_1_2_12_94_1
  doi: 10.1126/scitranslmed.3009835
– volume-title: Atlas of Immunology
  year: 2010
  ident: e_1_2_12_4_1
  doi: 10.1201/EBK1439802687
– ident: e_1_2_12_76_1
– ident: e_1_2_12_63_1
  doi: 10.1002/bdd.1952
– ident: e_1_2_12_35_1
  doi: 10.1083/jcb.98.4.1170
– ident: e_1_2_12_65_1
  doi: 10.2133/dmpk.DMPK-11-SH-059
– ident: e_1_2_12_46_1
  doi: 10.1080/17425255.2017.1360280
– ident: e_1_2_12_87_1
  doi: 10.1016/j.ejpb.2016.01.009
– ident: e_1_2_12_73_1
  doi: 10.1056/NEJMoa063842
– ident: e_1_2_12_5_1
  doi: 10.1038/256495a0
– ident: e_1_2_12_39_1
  doi: 10.1208/s12248-012-9369-y
– ident: e_1_2_12_18_1
  doi: 10.1055/s-0034-1368173
– ident: e_1_2_12_74_1
– ident: e_1_2_12_86_1
  doi: 10.2165/11530960-000000000-00000
– ident: e_1_2_12_13_1
  doi: 10.1038/nri2761
– ident: e_1_2_12_36_1
  doi: 10.1111/j.1365-2125.2007.02914.x
– ident: e_1_2_12_97_1
  doi: 10.4161/mabs.26436
– ident: e_1_2_12_42_1
  doi: 10.1074/jbc.M115.692434
– ident: e_1_2_12_61_1
  doi: 10.4161/mabs.24981
– ident: e_1_2_12_17_1
  doi: 10.1002/jps.21183
– ident: e_1_2_12_95_1
  doi: 10.3390/biomedicines4020012
– ident: e_1_2_12_52_1
  doi: 10.3389/fphar.2014.00174
– ident: e_1_2_12_38_1
  doi: 10.1073/pnas.1408766112
– ident: e_1_2_12_67_1
  doi: 10.2165/11537430-000000000-00000
– ident: e_1_2_12_24_1
  doi: 10.1089/cbr.2009.0627
– ident: e_1_2_12_66_1
  doi: 10.4161/mabs.3.1.13799
– ident: e_1_2_12_75_1
  doi: 10.1111/cts.12459
– ident: e_1_2_12_77_1
  doi: 10.1080/19420862.2016.1167294
– ident: e_1_2_12_16_1
  doi: 10.1016/j.drudis.2006.08.005
– ident: e_1_2_12_47_1
  doi: 10.1002/jps.22276
– ident: e_1_2_12_31_1
  doi: 10.2165/11535960-000000000-00000
– ident: e_1_2_12_19_1
  doi: 10.1002/jcph.365
– ident: e_1_2_12_81_1
  doi: 10.1002/psp4.12162
– ident: e_1_2_12_27_1
  doi: 10.1158/0008-5472.CAN-10-2277
– ident: e_1_2_12_29_1
  doi: 10.1002/bdd.1994
– ident: e_1_2_12_40_1
  doi: 10.1007/s40262-015-0361-4
– ident: e_1_2_12_78_1
  doi: 10.1007/s00280-011-1806-6
– ident: e_1_2_12_20_1
  doi: 10.1208/s12248-012-9367-0
– ident: e_1_2_12_23_1
  doi: 10.1002/jps.20178
– ident: e_1_2_12_92_1
  doi: 10.1073/pnas.91.12.5705
– ident: e_1_2_12_43_1
  doi: 10.1093/glycob/cwr027
– ident: e_1_2_12_45_1
  doi: 10.3389/fimmu.2015.00109
– ident: e_1_2_12_32_1
  doi: 10.1128/AAC.01285-13
– ident: e_1_2_12_30_1
  doi: 10.1038/nri2155
– ident: e_1_2_12_28_1
  doi: 10.4161/mabs.23684
– ident: e_1_2_12_93_1
  doi: 10.1111/bph.14021
– ident: e_1_2_12_79_1
  doi: 10.1007/s10928-010-9156-2
– ident: e_1_2_12_1_1
  doi: 10.1080/19420862.2016.1269580
– ident: e_1_2_12_15_1
  doi: 10.1016/j.ijpharm.2013.02.030
– ident: e_1_2_12_68_1
– ident: e_1_2_12_64_1
  doi: 10.1177/0091270009337134
– ident: e_1_2_12_8_1
  doi: 10.2741/2749
– ident: e_1_2_12_51_1
  doi: 10.1002/jps.24430
– volume: 13
  start-page: 1619
  year: 2008
  ident: e_1_2_12_7_1
  article-title: Humanization of antibodies
  publication-title: Front. Biosci.
– ident: e_1_2_12_84_1
  doi: 10.1016/j.molimm.2015.01.003
– ident: e_1_2_12_96_1
  doi: 10.1080/19420862.2015.1136043
– ident: e_1_2_12_34_1
  doi: 10.4161/mabs.26008
– ident: e_1_2_12_71_1
  doi: 10.1200/JCO.2014.58.1082
– ident: e_1_2_12_90_1
  doi: 10.1080/19420862.2016.1267089
– ident: e_1_2_12_56_1
  doi: 10.4161/mabs.28719
– ident: e_1_2_12_54_1
  doi: 10.1016/j.jim.2005.06.014
– ident: e_1_2_12_60_1
  doi: 10.1073/pnas.1421779112
– ident: e_1_2_12_3_1
– ident: e_1_2_12_82_1
  doi: 10.1002/psp4.12130
– year: 2016
  ident: e_1_2_12_83_1
  article-title: Clinical Pharmacology: a Discipline at the Nexus Between Translational Science and Precision Medicine: Commentary on “Enhancing Value of Clinical Pharmacodynamics in Oncology Drug Development: An Alliance Between Quantitative Pharmacology and Translational Science”
  publication-title: Clin. Pharmacol. Ther.
– ident: e_1_2_12_26_1
  doi: 10.1517/17425255.2012.643868
– ident: e_1_2_12_91_1
  doi: 10.1158/1535-7163.MCT-17-0657
SSID ssj0063685
Score 2.5545394
Snippet The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 540
SubjectTerms Tutorial
Title Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.12567
https://www.ncbi.nlm.nih.gov/pubmed/29877608
https://www.proquest.com/docview/2051665687
https://pubmed.ncbi.nlm.nih.gov/PMC6226118
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swED_aBEZfxtqtbbY2aGMPe8lIbFmS6VNbWtLCSmhTyMPA6Ms0tMhjdh723-8kf5DQFvpiDD4Z-04n_U7S_Q7gO5exyHOBkWpiQgmzaKSUwVDFKDsWeRTzmu3zhk3v6fUiWWzBSZsLU_NDdAtu3jPCeO0dXKpyzcl1Vf7E2Znxbej71FpPnB_RWTsMM8-sHrIhE3R5BCYNrZA_xtM13ZyMniHM5wcl1wFsmIEuP8D7BjqS09rWu7Bl3R68-9Vsjn-E33PPR4D9iRSOoK8W-qkIDVy1VIX5R2YNTfUjint2ZiKdIVdVSdqqnfXqHVk6EniPydqJok9wf3kxP5-OmuIJI00Fzjw5xgKpUHRsE0alsIxrYcYatRFH6JMGXdtwLUWSK005R1wnmZHc-uuEKhvvQ88Vzh4CEUbINKWIPTQG0mqSUiusYLmhMqVqogfwo9ViphtmcV_g4ilrIwxUeBYUPoBvneifmk7jJaGvrSky7Ox-B0M6W6zKLMIhhCECFShzUJume02UCs7ZWAyAbxitE_BE2ptP3PIhEGozxKAYaOF_BPO-_mXZ-fwu3Hx-u-gX2EGQJer8xSPoVX9X9hiBTKWGocPilS_4EPpnFzez22FYFPgPZbDzpw
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Li9swEB6yKXR7WfpudtuuWnroJcVxZEmGvZTQJekmIdAEcigYvcyGLvKycQ799x3JDxLSQi_G4JGxZzSab_T4BuATl0OR5wIz1cSEEmZxXymDqYpRNhJ5POQV2-ecjVf0-zpZd-CqOQtT8UO0E27eM8J47R3cT0jvebkut18wPDN-Ao8oi7l3y5gumnGYeWr1cBwyQZ9HZFLzCvl9PG3Tw2h0BDGPd0ruI9gQgq6fwlmNHcnXytjPoGPdc3g8q1fHX8DPpSckwA5FCkfQWQt9V4QGrtyowvwmi5qn-heKe3pmIp0hk3JLmrKd1fQd2TgSiI_J3pail7C6_rYcjft19YS-pgJDT47JQCoUjWzCqBSWcS1MpFEbwxid0qBvG66lSHKlKecI7CQzklt_HVBlh6-g6wpn3wARRsg0pQg-NGbSapBSK6xguaEypWqge_C50WKma2pxX-HiLmtSDFR4FhTeg4-t6H3Fp_E3oQ-NKTLs7X4JQzpb7LZZjGMIQwgqUOZ1ZZr2NXEqOGeR6AE_MFor4Jm0D5-4zW1g1GYIQjHTwv8I5v33l2Wj5Y9wc_7_opdwOl7Optl0Mr-5gCeIuER1mPEtdMuHnX2HqKZU70Pn_QN3bPOd
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFD60CZS-jF3b7KqNPewlxXFkSWZPIVto1q4UFo9SCkY3s7Agh8V52L_fkXwhoRvsxRh8ZOxz0fmOLp8A3nM5FkUhsFJNTDjCLB4qZbBUMcpGoojHvGb7vGLnGf1yk9wcwMd2L0zND9ENuPnICP21D_C1KXaCXFebM8zOjB9C37PkoUv3J9-z26ztiJnnVg_7IRMMeoQmDbGQX8jTNd5PR_cw5v2lkrsQNuSg2UN40IBHMqmt_QgOrHsMR1-b6fEncLfwjAToUaR0BKO11KsyNHDVUpXmN7luiKp_orjnZybSGTKvNqQ9t7MevyNLRwLzMdlZU_QUstnnxfR82ByfMNRUYO4psBpIhaKRTRiVwjKuhYk0amMcY1QaDG7DtRRJoTTlHJGdZEZy668jquz4GfRc6ewpEGGETFOK6ENjKa1GKbXCClYYKlOqRnoAH1ot5rrhFvdHXKzytsZAhedB4QN414mua0KNvwm9bU2Ro7v7OQzpbLnd5DF2IgwxqECZk9o03WviVHDOIjEAvme0TsBTae8_ccsfgVKbIQrFUgv_I5j331-WTxffws3z_xd9A0fXn2b55fzq4gUcI-IS9WbGl9Crfm3tK0Q1lXrdeO8fquz0lQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tutorial+on+Monoclonal+Antibody+Pharmacokinetics+and+Its+Considerations+in+Early+Development&rft.jtitle=Clinical+and+translational+science&rft.au=Ovacik%2C+Meric&rft.au=Lin%2C+Kedan&rft.date=2018-11-01&rft.eissn=1752-8062&rft.volume=11&rft.issue=6&rft.spage=540&rft_id=info:doi/10.1111%2Fcts.12567&rft_id=info%3Apmid%2F29877608&rft.externalDocID=29877608
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1752-8054&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1752-8054&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1752-8054&client=summon